India's Gufic Bioscience to collaborate with Australia's Selvax

2 min read | March 10, 2022 07:23 PM AEDT | By Samta

Google News:

India's Gufic Bioscience to collaborate with Australia's Selvax — Image source: © Kantver | Megapixl.com

Recent News

Could Housing Concerns Change The JB Hi-Fi Story?

Megaport’s Equity Raise: Growth Accelerator or Dilution Concern?

Is Life360’s Growth Story Entering A New Phase?

How Does a Mining Portfolio Stay Balanced Across Cycles?

Make Kalkine Media
My Trusted Source

Highlights

Australia based Selvax and India's Gufic Biosciences are entering into a research and collaboration agreement.

Orbit Financial Capital is the exclusive financial advisor to the transaction.

Selvax aims to develop safe, effective, and immunological-based treatments targeting a range of solid tumours.

India's Gufic Biosciences Limited is entering into a research and collaboration agreement with West Australia based Selvax Pty Ltd to boost Selvax's cancer immunotherapy treatment commercialisation.

The deal

As per the deal, Gufic will undertake mutually agreed development activities while Selvax will provide exclusive commercial rights for its immunotherapy in India.

Selvax will further provide an equal share of future revenues, likely based on future sales of the product in Europe. However, the product sales will be subject to regulatory approval from Indian and European authorities.

Selvax aims to develop safe, effective, and immunological-based treatments targeting a range of solid tumours.

Watch more - What We Know About Hong Kong’s Likely Covid Lockdown?

Image source - © Krishnacreations | Megapixl.com

Selvax's innovative technology targets the tumour microenvironment in cancer cells. It stimulates an immune response, further allowing the technology to overcome significant challenges which were earlier faced with other cancer immunotherapies. These major challenges also include poor response rates and potentially serious toxicity.

If the technology is successfully deployed, it might help treat novel cancer in animals and humans.

Orbit Financial Capital is the exclusive financial advisor to the transaction.

Bottom line

As Gufic has a long track record of innovation and new drug development, Selvax considers Gufic as its ideal collaboration partner.

Gufic has continued to demonstrate its efforts to bring innovation in the medical field by expanding its portfolio in cancer immunotherapy. Cancer immunotherapy is one of the most rapidly growing segments of the global pharmaceutical market.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.